AFFIMED NV (AFMD)
NL0015001ZQ0 - Common Stock
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Affimed Reports Third Quarter 2024 Financial Results & Business Update
AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate...
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
MANNHEIM, Germany, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed to Present at the Cantor Global Healthcare Conference 2024
Affimed to Present at the Cantor Global Healthcare Conference 2024
MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Affimed Reports Second Quarter 2024 Financial Results & Business Update
AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable...
Affimed Appoints Shawn M. Leland as Chief Executive Officer
Affimed Appoints Shawn M. Leland as Chief Executive Officer
MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company...
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
AFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Affimed Reports First Quarter 2024 Financial Results & Business Update
Affimed Reports First Quarter 2024 Financial Results & Business Update
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - -...
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4...
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer ...
Affimed Announces Annual General Meeting of Shareholders
Affimed Announces Annual General Meeting of Shareholders
MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
7 Penny Biotech Stocks to Triple Your Investment
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors,...
Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential
Lower interest rates will bring speculators back into small-cap stocks; with that in mind here are three small-cap stocks to buy now.
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to...
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR...
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023
AFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Affimed (NASDAQ:AFMD) just reported results for the fourth quarter of 2023.Affi...